公司資料
Soleno Therapeutics 股價、新聞與催化劑
- 股票代碼:
- SLNO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
53.01 USD (+0.04%)
收盤價
最後更新: 2026年5月15日
2.76B USD
市值
股價為何變動
Current closing-price context is not available for SLNO.
公司概覽
Prader-Willi Syndrome Focus
Soleno Therapeutics develops and commercializes therapies for rare diseases. Its initial franchise addresses hyperphagia, the persistent and potentially life-threatening hunger associated with Prader-Willi syndrome.
VYKAT XR
VYKAT XR is a once-daily extended-release formulation of diazoxide choline approved in the United States for hyperphagia in adults and children age four and older with Prader-Willi syndrome. It is the company’s first commercial product.
International Expansion
Soleno has begun building a commercial patient and prescriber base in the United States and has submitted a European marketing application. The company plans to use the U.S. launch infrastructure and disease-community relationships to support expansion into additional territories.
未來催化劑
- Soleno’s catalysts are DCCR in Prader-Willi syndrome and the next regulatory / commercialization steps around that program. The stock is still driven by whether the rare-disease opportunity can keep advancing.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。